Some long-term data are available for pioglitazone, another PPAR-γ agonist, but those data were not actively controlled, are based on clinic measurements and were gained in a sub-population of people with overt cardiovascular disease [37]. This evidence concerns the gene PPARG and cardiovascular disorder.